中医药联合分子靶向治疗非小细胞肺癌研究进展
Research Progress on Molecular Targeted Therapy of Non-small Cell Lung Cancer Combined with Traditional Chinese Medicine
张帆 1朱玉龙2
作者信息
- 1. 新疆医科大学第四临床医学院 新疆 乌鲁木齐 830000
- 2. 新疆医科大学附属中医医院
- 折叠
摘要
非小细胞肺癌(NSCLC)是肺癌最常见的类型,靶向治疗是NSCLC的首选治疗方案.尽管靶向药物治疗已经在NSCLC的治疗中取得了显著的进展,但由于肿瘤异质性以及肿瘤细胞的逃逸机制,单一的药物治疗仍然存在一定的局限性.因此,探索中医联合靶向药物治疗NSCLC的研究越来越受到重视.本文将对中医药联合靶向治疗在NSCLC领域的研究进行归纳总结,以期为中医药联合靶向治疗NSCLC提供理论依据.
Abstract
Non-small cell lung cancer(NSCLC)is the most common type of lung cancer,and targeted therapy is the preferred treatment option for NSCLC.Despite significant progress in targeted drug therapy for NSCLC,there are still limitations due to tumor heterogeneity and tumor cell escape mechanisms.Therefore,more and more attention has been paid to the study of traditional Chinese medicine combined with targeted drug therapy in the treatment of NSCLC.This article summarizes the research on traditional Chinese medicine combined with targeted therapy in the field of NSCLC,in order to provide a theoretical basis for the combination therapy of traditional Chinese medicine and targeted therapy for NSCLC.
关键词
靶向治疗/辨证论治/基因突变/血管内皮生长因子受体抑制剂Key words
Targeted therapy/Syndrome differentiation and treatment/Gene mutation/Inhibitor引用本文复制引用
基金项目
新疆维吾尔自治区天山创新团队计划项目(2023D14004)
"天山英才"-青年科技拔尖人才项目(2022TSYCCX0028)
出版年
2024
国家科技期刊平台
NSTL
万方数据